SCHEMBL4075888

SCHEMBL4075888

O=C(O)c1cccc(-c2cc3ncnc(NCCc4ccc(O)cc4)c3s2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.48
MAP3K8 P41279 2/20 0.47
HTT P42858 3/20 0.46
AURKA O14965 3/20 0.46
NR2F2 P24468 1/20 0.45
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44
PIP4K2C Q8TBX8 1/20 0.43
EGFR P00533 1/20 0.43
TTBK1 Q5TCY1 1/20 0.43
TTBK2 Q6IQ55 1/20 0.43
RAB9A P51151 2/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
NPC1 O15118 1/20 0.42
STK17B O94768 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071814 0.90 FLT1 (0.55) FLT1HTTAURKANR2F2PIP4K2C
SCHEMBL4068423 0.85 MAP3K8 (0.51) FLT1MAP3K8HTTAURKANR2F2
SCHEMBL4072402 0.85 HTT (0.48) FLT1HTTAURKANR2F2PIP4K2C
SCHEMBL3937824 0.84 STK17B (0.58) FLT1MAP3K8HTTAURKANR2F2
SCHEMBL4071720 0.82 CYP1A2 (0.47) FLT1HTTAURKANR2F2PIP4K2C
SCHEMBL13242725 0.82 AURKA (0.59) FLT1AURKAEGFR
SCHEMBL4068541 0.82 FLT1 (0.48) FLT1MAP3K8EGFRRAB9ACSNK2A2
SCHEMBL4067658 0.82 FLT1 (0.61) FLT1HTTEGFRRAB9ANPC1
SCHEMBL4070516 0.80 PDPK1 (0.52) FLT1HTTEGFRRAB9ANPC1
SCHEMBL4072529 0.79 TYK2 (0.60) FLT1MAP3K8HTTEGFRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 FLT1 3521/4885MAP3K8 1493/4885HTT 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.